West Roxbury, MA, United States of America

Gabriel Martinez-Botella

This inventor holds 17 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Protein Kinase Inhibitors. Top assignee: Vertex Pharmaceuticals, Inc.. Active years: 2007-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gabriel Martinez-Botella. Retrieved from https://idiyas.com/inventor/gabriel-martinez-botella-7rscn3tk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 5)

% Patents Active = 29.4

CIPO Patents = 1

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 6.3

ph-index = 10

Forward Citations = 256(Granted Patents)

Location History:

W. Roxbury, MA (US) (2007)
Wayland, MA (US) (2012 - 2014)
West Roxbury, MA (US) (2008 - 2015)

Company Filing History:

17 out of 1,168

Vertex Pharmaceuticals, Inc.

patents

Years Active: 2007-2015

Loading Chart...

Areas of Expertise:

Azaindoles

Pyrrolopyridines

Janus Kinases

Bicyclic Derivatives

ERK Protein Kinase

Deazapurines

Selective Inhibitors

Heterocyclic Compounds

Ion Channels

Prodrugs

Pyridine Inhibitors

Pyrrole Inhibitors

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9120790 - Azaindoles useful as inhibitors of Janus kinases (2015-09-01),

2. 8921376 - Pyrrolopyridines useful as inhibitors of protein kinase (2014-12-30),

3. 8822681 - Azaindoles useful as inhibitors of janus kinases (2014-09-02),

4. 8741912 - Deazapurines useful as inhibitors of Janus kinases (2014-06-03),

5. 8686143 - Compounds useful as inhibitors of Janus kinases (2014-04-01),

6. 8580802 - Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases (2013-11-12),

7. 8536195 - Bicyclic derivatives as modulators of ion channels (2013-09-17),

8. 8450489 - Azaindoles useful as inhibitors of janus kinases (2013-05-28),

9. 8314125 - Bicyclic derivatives as modulators of ion channels (2012-11-20),

10. 8163917 - Azaindoles useful as inhibitors of Janus kinases (2012-04-24),

11. 7767816 - Azaindoles useful as inhibitors of janus kinases (2010-08-03),

12. 7745629 - Bicyclic derivatives as modulators of ion channels (2010-06-29),

13. 7501415 - Selective inhibitors of ERK protein kinase and uses thereof (2009-03-10),

14. 7462612 - Pyridine inhibitors of ERK2 and uses thereof (2008-12-09),

15. 7358258 - Prodrugs of an ERK protein kinase inhibitor (2008-04-15),

Title: Biography of Gabriel Martinez-Botella

Introduction: Gabriel Martinez-Botella is a prominent inventor based in West Roxbury, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit protein kinases.

Latest Patents: Gabriel holds 17 patents, with his latest inventions focusing on Azaindoles and Pyrrolopyridines. The Azaindoles patent relates to compounds that serve as inhibitors of Janus kinases, providing methods for treating various diseases and conditions. The Pyrrolopyridines patent also addresses inhibitors of protein kinases, specifically targeting JAK family and ROCK family kinases, along with their pharmaceutical applications.

Career Highlights: Gabriel is currently employed at Vertex Pharmaceuticals, Inc., where he continues to innovate and develop new therapeutic solutions. His work has been instrumental in advancing the understanding and treatment of diseases related to protein kinases.

Collaborations: Throughout his career, Gabriel has collaborated with notable colleagues, including Luc J Farmer and Albert Charles Pierce. These partnerships have fostered a collaborative environment that enhances research and development efforts.

Conclusion: Gabriel Martinez-Botella is a distinguished inventor whose work in the pharmaceutical industry has led to significant advancements in the treatment of various medical conditions. His dedication to innovation and collaboration continues to impact the field positively.

Profile summary based on public USPTO records.